ThinkstockDrug developer Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) watched its shares plummet 35% yesterday following a report that rheumatoid arthritis treatment it was developing with AstraZeneca plc (NYSE: AZN) did not show the expected benefits…
ThinkstockBiotech giant Amgen Inc. (NASDAQ: AMGN) made a series of moves after markets closed last night that appear to add up to an effort giving something to everybody. First out of the chute was…
ThinkstockTeva Pharmaceutical Industries Ltd. (NYSE: TEVA) is not getting any great warm welcome out of its 2012 investor meeting webcast. The company may soon find itself in a position where the turnaround just can’t…
ThinkstockJohnson & Johnson (NYSE: JNJ) may have an even larger winner with its prostate cancer drug called ZYTIGA. The Food & Drug Administration has approved an expanded indication in men for the treatment of…
ThinkstockBiopharmaceutical company Amarin Corp. PLC (NASDAQ: AMRN) announced after markets closed last night that it has received $100 million in nonequity financing from an investment fund managed by Pharmakon Advisors. Calling the cash infusing…
U.S. medical instruments and supplies maker Baxter International Inc. (NYSE: BAX) said this morning that it has signed a definitive agreement to acquire privately held Swedish dialysis product firm Gambro AB for a total…
PDL BioPharma Inc. (NASDAQ: PDLI) shareholders are going to be scratching their heads trying to figure out what is going on. The company announced after the close on Monday that Bruce Tomlinson has resigned…
ThinkstockIdenix Pharmaceuticals Inc. (NASDAQ: IDIX) was covered this morning in our analyst upgrades and downgrades daily summary, but call is worth a closer look. Deutsche Bank initiated the small biotech with a BUy rating. What…
ThinkstockMerck & Co. (NYSE: MRK) has joined the dividend hike brigade. We were not sure if the pharmaceutical giant was going to hike its payout, but it has. The company’s board of directors increased…
ThinkstockACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) is proving to be the big winner of the day. In fact, it may be the winner of the month on any percentage gain in a day. Its shares…
ThinkstockIn an announcement for its annual investor conference tomorrow, UnitedHealth Group Inc. (NYSE: UNH) reaffirmed its earnings per share (EPS) forecast for 2012 at $5.20 to $5.25. But in its first estimate of fiscal…
ThinkstockThe U.S. Securities and Exchange Commission (SEC) today filed criminal charges against a former SAC Capital Advisors hedge-fund manager related to an insider trading scheme that generated profits and avoided losses of $276 million…
ThinkstockDynavax Technologies Corp. (NASDAQ: DVAX) is feeling the wrath of the markets after an FDA panel said that there was insufficient data to support its investigational Hepatitis B drug called Hepislav. The Vaccines and…
ThinkstockWhen biotech stocks become as big as some of the second-tier drug stocks, it represents billions of dollars worth of value when these move 5% or 10%. That is exactly what we are seeing…
ThinkstockWe have tracked the key short interest changes in the following biotech and emerging pharma companies: Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Amgen Inc. (NASDAQ: AMGN), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Biogen Idec Inc. (NASDAQ:…